News & Events

  • 02 Jul 2016
  • Hetero launches Biosimilar Bevacizumab
  • Hetero, one of India's leading generic pharmaceutical companies, today announces the launch of Biosimilar 'Bevacizumab' in India for the treatment of metastatic colorectal cancer (mCRC) under the brand name 'CizumabTM' Read more
  • 16 Dec 2015
  • Correct trademark name of Ledipasvir-Sofosbuvir is 'Ledifos'
  • This is with reference to the press release dated 9th December 2015 on the DCGI approval for Ledipasvir-Sofosbuvir. Hetero would like to clarify that there was an error in the brand name of the fixed-dose combination drug 'Ledipasvir-Sofosbuvir'. It was published as Ledisof. Read more